This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

Validation of Alzheimer’s disease CSF and plasma biological markers: the multicentre reliability study of the pilot European Alzheimer’s Disease Neuroimaging Initiative (E-ADNI)


Buerger, Katharina, Frisoni, Giovanni, Uspenskaya, Olga, Ewers, Michael, Zetterberg, Henrik, Geroldi, Cristina, Binetti, Giuliano, Johannsen, Peter, Rossini, Paolo Maria, Wahlund, Lars-Olof, Vellas, Bruno, Blennow, Kaj, Hampel, Harald


Experimental Gerontology, Volume: 44, No.: 9, Pages.: 579-585

Year of Publication



Background: Alzheimer’s Disease Neuroimaging Initiatives (“ADNI”) aim to validate neuroimaging and biochemical markers of Alzheimer’s disease (AD). Data of the pilot European-ADNI (E-ADNI) biological marker programme of cerebrospinal fluid (CSF) and plasma candidate biomarkers are reported.; Methods: Six academic EADC centres recruited 49 subjects (healthy controls, subjects with mild cognitive impairment (MCI) and AD). We measured CSF beta-amyloid 42 (CSF Abeta42), total tau-protein (t-tau), phosphorylated tau-proteins (P-tau181, P-tau231), plasma beta-amyloid 40 and 42 (Abeta40/Abeta42). Immediate fresh shipment was compared to freezing and later shipment on dry ice.; Results: CSF T-tau (fresh samples) was increased in AD versus controls (p=0.049), CSF Abeta42 (frozen samples) was decreased in MCI and AD (p=0.02), as well as plasma Abeta40 (fresh and frozen samples) in AD (p=0.049 and p=0.016). Pooled values of neurochemical parameters and ratios thereof were different between centres (p<0.005). Analysis of frozen samples yielded higher diagnostic accuracy than immediate fresh shipment with 100% (fresh: 100%) correctly classified in control subjects, 100% (78%) in MCI, 91% (91%) in AD.; Conclusion: The use of frozen rather than fresh samples renders higher diagnostic accuracy within a multicentre context. We confirmed the feasibility of a multicentre AD biomarker programme for future clinical trials.;

Bibtex Citation

@article{Buerger_2009, doi = {10.1016/j.exger.2009.06.003}, url = {}, year = 2009, month = {sep}, publisher = {Elsevier {BV}}, volume = {44}, number = {9}, pages = {579--585}, author = {Katharina Buerger and Giovanni Frisoni and Olga Uspenskaya and Michael Ewers and Henrik Zetterberg and Cristina Geroldi and Giuliano Binetti and Peter Johannsen and Paolo Maria Rossini and Lars-Olof Wahlund and Bruno Vellas and Kaj Blennow and Harald Hampel}, title = {Validation of Alzheimer's disease {CSF} and plasma biological markers: The multicentre reliability study of the pilot European Alzheimer's Disease Neuroimaging Initiative (E-{ADNI})}, journal = {Experimental Gerontology} }


adult, aged, aged, 80 and over, alzheimer disease, amyloid betapeptides, apolipoproteins e, biological markers, blood, cerebrospinal fluid, diagnosis, diagnostic use, feasibility studies, female, humans, male, methods, middle aged, peptide fragments, pilot projects, reproducibility of results, tau proteins

Countries of Study

Germany, Italy, UK

Types of Dementia

Alzheimer’s Disease, Mild Cognitive Impairment (MCI)

Types of Study

Cohort Study

Type of Interventions

Diagnostic Target Identification

Diagnostic Targets

Biological Testing